Written question asked by John Hayes (Conservative) on Wednesday, 1 July 2026, in the House of Commons. It was due for an answer on Monday, 6 July 2026. It was answered by Kanishka Narayan (Labour) on Friday, 10 July 2026 on behalf of the Department for Science, Innovation and Technology.
Diabetes: Research
- Question
-
To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made of the UK's position globally in respect of research into beta cell preservation, regeneration and replacement therapies for type 1 diabetes.
- Answer
-
Through UK Research and Innovation (UKRI), including UKRI’s Medical Research Council (MRC), the Government supports a broad portfolio of research relevant to Type 1 diabetes. This includes work on pancreatic biology, immunology, and cell replacement approaches, alongside wider research into the underlying mechanisms of the disease. Funding is awarded through open, competitive processes based on scientific excellence, ensuring the UK remains well placed to contribute to advances in areas such as beta cell therapies.
The Department of Health and Social Care also funds research through the National Institute for Health and Care Research, which supports high-quality research to improve the diagnosis, treatment and management of Type 1 diabetes.
Secondary information
- Type
- Written question
- Reference
- 14779
- Session
- 2026-27
- Subjects
- Diabetes Research
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-07-10 14:19:26 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/14779
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/14779
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/14779